Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication Clinical observations from CLN-978 B-NHL study show rapid, deep, and sustained B cell depletion and clinical activity Corporate name change to Cullinan Therapeutics reflects strategic expansion into autoimmune diseases Cullinan Therapeutics to host a virtual investor event taking place on April 16 at 8:00 am ET CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Th ...